ESR1 and breast cancer: Thus, HER2+ breast cancer exhibits a distinct and aggressive clinical presentation compared with estrogen receptor (ER)-positive, HER2-negative breast cancer, which is a major subtype of breast cancer often exhibiting less aggressive behavior [3].